Skip to main contentSkip to navigationSkip to search

Press release

Camurus Annual Report for 2021

06 April 2022 | Regulatory

Lund, Sweden — 6 April 2021 — Camurus (CAMX) today announces that the Annual Report for 2021 now is available at the company’s website: www.camurus.com, and as an attachment to this press release. The Swedish version of the Annual Report is also available on the website in European Single Electronic Format (ESEF).

“2021 was a productive and successful year for Camurus where we, under challenging market conditions, continued to advance our business towards our strategic goals. Revenues grew by high double digits and the operating result continued to improve whilst we made significant investments in our pipeline of innovative medicines. We received new and extended regulatory approvals for Buvidal® for the treatment of opioid dependence and advanced key development programs towards the market”, says Fredrik Tiberg, President and CEO of Camurus.

The Annual Report also includes Camurus’ sustainability report.

For more information
Fredrik Tiberg, President & CEO
Tel. +46 (0)46 286 46 92

fredrik.tiberg@camurus.com

Fredrik Joabsson, Chief Business Development Officer
Tel. +46 (0)70 776 17 37

ir@camurus.com

About Camurus
Camurus is a Swedish science-led biopharmaceutical company committed to developing and commercializing innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the company’s proprietary FluidCrystal® drug delivery technologies and its extensive R&D expertise. Camurus’ clinical pipeline includes products for the treatment of cancer, endocrine diseases, pain and addiction, which are developed in-house and in collaboration with international pharmaceutical companies. The company’s shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit www.camurus.com.

This information is information that Camurus AB (publ) is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication at 10:00am CET on 6 April 2021.

TypeError: Cannot read properties of undefined (reading 'url')